Ad-hoc News
31.01.2012
biolitec AG decides public buyback of up to 500,000 shares at €1.70
Jena, January 31, 2012 – The management board of Jena-based biolitec AG, listed in the Prime Standard segment of the Frankfurt Stock Exchange (ISIN DE0005213409), has decided today to make a public offer to the holders of up to 500,000 bearer shares of no par value to buy their shares back, as in accordance with the authorisation granted in the General Meeting of November 17, 2009, and based on the approval of the board of directors.
The offering period will start on Thursday, February 9, 2012, and terminate on Thursday, February 23, 2012, at 2 o’clock p.m. (Frankfurt/Main time). Shareholders may tender their shares to the corporation at a price of 1.70 EUR per share in this time period. The biolitec AG may acquire up to 500,000 shares in the course of the offering. The shares bought back in the course of this offering will be withdrawn. Depending on the volume of the buyback, the share capital of currently 10,515,750 EUR will be reduced by up to 500,000 EUR to 10,015,750 EUR. Further details concerning the planned buyback are included in the offering document which is expected to be available for download from February 6, 2012, on the company’s website www.biolitec.de and in the electronic Federal Gazette (“elektronischer Bundesanzeiger).
Due to the buyback, biolitec’s shares will not be traded in the mid-cap index GEX® in the future anymore, in case the free float drops below the 25.1% boundary. In addition, biolitec calls attention to the fact that due to the planned downlisting into the Entry Standard segment already announced earlier, a number of institutional investors will not purchase the stock anymore because of their internal regulations.
The public buyback offer is intended to provide biolitec shareholders with the opportunity to sell, which is hampered by the share’s low liquidity in regular stock trading.
The technical processing of the share buyback programme is led by BankM, Subsidiary of biw Bank for Investments and Securities AG, Frankfurt/Main.
The information does not constitute an offer of or an invitation by or on behalf of biolitec AG or any of its subsidiaries to subscribe for or purchase securities of biolitec AG or any of its subsidiaries.
In particular, the information contained does not constitute an offer of secu-rities for sale or solicitation of an offer to buy securities in the United States of America.
